论文部分内容阅读
目的分析不同剂量伐昔洛韦联合胸腺肽治疗带状疱疹的临床效果和安全性。方法选择在杭州市余杭区妇幼保健院接受住院治疗的带状疱疹患者128例作为研究对象,随机分为使用常规剂量伐昔洛韦联合胸腺肽治疗的A组(64例)及大剂量伐昔洛韦联合胸腺肽治疗的B组(64例),观察患者接受治疗前后的水疱面积、有无新发水疱、结痂、脱痂等病情评分、疼痛评分,以及治疗过程中并发症发生率等情况。结果①治疗后,两组患者水疱面积、新发水疱、结痂及脱痂情况评分均显著低于治疗前(P<0.05),但是B组治疗后评分与A组比较差异无统计学意义(P>0.05);②治疗后,两组患者疼痛严重程度均低于治疗前(P<0.05),且B组患者的平均疼痛评分及严重疼痛患者比例均明显低于A组(P<0.05);③两组患者接受治疗后的并发症发生率比较差异无统计学意义(P>0.05)。结论大剂量伐昔洛韦在控制带状疱疹患者病情的同时,可以更有效地缓解患者疼痛感受,且不增加不良反应发生。
Objective To analyze the clinical effects and safety of different doses of valacyclovir combined with thymosin in the treatment of shingles. Methods A total of 128 patients with shingles admitted to Yuhwa District Maternal and Child Health Hospital were enrolled in this study. Patients were randomly divided into group A (64 cases) treated with conventional valacyclovir plus thymosin and high-dose valacyclovir The patients in group B (64 cases) treated with thymopentin combined with thymopentin were divided into two groups: the blister area before and after treatment, the new blisters, scabs and scabs, pain score and the incidence of complications in the course of treatment. Results ① After treatment, the blister area, new blisters, crusting and scab off were significantly lower in both groups than before treatment (P <0.05), but there was no significant difference between the two groups (P <0.05). After treatment, the severity of pain in both groups was lower than that before treatment (P <0.05), and the average pain scores and the proportion of severe pain patients in group B were significantly lower than those in group A (P <0.05) ; ③ There was no significant difference in the incidence of complications between the two groups after treatment (P> 0.05). Conclusions High-dose valacyclovir can control the pain of patients with herpes zoster while controlling the condition of herpes zoster without increasing the incidence of adverse reactions.